Navigation Links
SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
Date:9/10/2007

TAMPA, Fla.September 10, 2007--Accentia Biopharmaceuticals (NASDAQ: ABPI) announces evidence that most, if not all cases of chronic sinusitis (CS), are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic. The data were collected as part of the Companys ongoing pivotal Phase 3 clinical trial for its lead pharmaceutical product, SinuNase, an intranasal formulation of the antifungal amphotericin B 0.01% suspension. In order to be enrolled in the clinical trial, patients must have had well-documented CS based on a history of the requisite symptoms, nasal endoscopy findings, and CT scan demonstrating characteristic mucosal changes in the sinuses. At the time of enrollment, all patients have had nasal mucin collected. Subsequently, these specimens are being tested for eosinophilic major basic protein (eMBP). In the first fifty specimens now analyzed, all have been positive for eMBP, a toxic protein released by inflammatory cells in response to fungi. The Company believes that these findings strongly support a fungal-induced inflammation as the cause of CS.

SinuTest, the diagnostic used to measure eMBP in the nasal mucin, is a patented technology developed at the Mayo Foundation for Medical Education and Research. The technology is exclusively licensed to IMMCO Diagnostics, which has an exclusive commercialization agreement with Accentia Biopharmaceuticals. The Company believes that SinuTest will be a useful adjunct for identification of patients who are suspected of having CS and who may be candidates for treatment with SinuNase, assuming FDA approval.

As previously announced, Accentia has received Fast Track status from the Food and Drug Administration (FDA) for SinuNase, and it is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial with severe CS patients at more than 50 sites across the U.S. To the knowledge of the Company, this is the first and only Phase 3 clinica
'/>"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Worlds largest rainforest drying experiment completes first phase
3. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. NIH announces phase III clinical trial of creatine for Parkinsons disease
8. Farm kids almost twice as likely to die from injury as children overall
9. Chronic pain up almost 40 percent among US workers in past decade
10. Hunger in America rises by 43 percent over last five years
11. Method slashes quantum dot costs by 80 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... a share of grants totalling over 1m to target ... Dr. Declan Bates, a senior lecturer in the Department ... of 1,068,000 in the form of just two research ... Council (EPSRC) and the other from the Biotechnology and ...
... molecular mechanisms by which plants protect themselves from oxidation ... a team of researchers has discovered a molecular dimmer ... moving through the system of light harvesting proteins. This ... artificial photosynthesis systems that could provide the world with ...
... Fla. Two University of Miami (UM) students have ... Foundation (NSF) for their doctoral work on coral reefs. ... years of support for their work in the laboratory ... Division of Marine Biology and Fisheries at UMs Rosenstiel ...
Cached Biology News:Engineer to spearhead research into cell metabolism and medical injuries 2Berkeley researchers identify photosynthetic dimmer switch 2Berkeley researchers identify photosynthetic dimmer switch 3Berkeley researchers identify photosynthetic dimmer switch 4Everything's coming up corals 2Everything's coming up corals 3
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
(Date:10/19/2014)... report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla Market ... (2011 - 2016)," analyzes the chocolate market by ... market drivers, restraints, and opportunities for the chocolate market ... chocolate market is expected to grow from $83.2 billion ... CAGR of 2.7% from 2011 to 2016. , Get ...
(Date:10/18/2014)... The “Human Insulin Market- by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/18/2014)... Asia-Pacific hardware encryption display market report defines and segments ... of revenue. This market was valued $5,154.0 million in ... 2018, at a CAGR of 58.4% from 2013 to ... hardware encryption market report, to get an idea of ... of the segmentation of the market, and is supported ...
Breaking Biology Technology:The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... WEST CONSHOHOCKEN, Pa., Nov. 12 GEL Interactive,Technologies, ... Kent,Senior Product Director, will be a featured speaker ... Annual Forum on Defining Appropriate,and Effective Interactions with ... 5th Annual Forum provides a platform for attendees ...
... MELBOURNE, Australia, Nov. 12 Phosphagenics,Limited ("Phosphagenics") (ASX: ... initiated a phase 1 human clinical trial ... the targeted delivery of a leading non ... compare the,bioavailability and penetration of the topically ...
... EMERYVILLE, Calif., Nov. 12 Bionovo, Inc.,(Nasdaq: BNVI ... to the,company,s Scientific Advisory Board. Dr. Weiss is a ... a leading researcher,at the Cardiovascular Research Institute and the ... (UCSF)., "We are very excited to have Ethan ...
Cached Biology Technology:Cadient Group's GEL Interactive Technologies to Present and Exhibit at CBI's 5th Annual Forum 2Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 3
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... incubation trays are disposable trays ... antigens that have been blotted ... has eight 10.5 cm x ... strips cut from blotted membrane ...
... in permanent mounting media. It is ... immunohistochemical organic insoluble substrates such as ... and any other organic solvent compatible ... can be used for histology and ...
... The Gene Inspector can perform many sophisticated DNA ... is much more than just another sequence analysis ... entire suite of analyses to be performed each ... design custom style sheets which specify exactly how ...
Biology Products: